Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. [electronic resource]
Producer: 20171207Description: 349-354 p. digitalISSN:- 2317-6385
- Androgen Receptor Antagonists -- administration & dosage
- Antineoplastic Agents, Hormonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Cost-Benefit Analysis
- Docetaxel
- Humans
- Male
- Prostatic Neoplasms -- drug therapy
- Quality-Adjusted Life Years
- Taxoids -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.